Medicare Enrolled
Dr. Hitendra Rambhia, MD
Hematology & Oncology · Brooklyn, NY
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rambhia from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rambhia?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rambhia
Dr. Hitendra Rambhia is a hematology & oncology specialist in Brooklyn, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Rambhia performed 3,570 Medicare services across 907 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rambhia received a total of $12,148 from 46 pharmaceutical and/or device companies across 319 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rambhia is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 25% volume in NY
$12,148 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,570
Medicare services
Top 25% in NY for hematology & oncology
907
Unique beneficiaries
$63
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~178 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
761 | $72 | $156 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
552 | $80 | $128 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
523 | $106 | $225 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
503 | $8 | $15 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
340 | $13 | $55 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
197 | $52 | $84 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
143 | $153 | $295 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
118 | $111 | $198 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
100 | $62 | $200 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
100 | $19 | $100 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 99 | $0 | $0 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
60 | $0 | $0 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
42 | $117 | $255 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
32 | $141 | $277 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.6% high complexity
14.0% medium
80.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,148
Total received (2018-2024)
Avg $1,735/year across 7 years
Top 23% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
319
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,252 (59.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,742 (14.3%)
Other
Charitable contributions, space rental, and other categories
$1,631 (13.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,523 (12.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,415
2023
$1,789
2022
$2,060
2021
$2,383
2020
$252
2019
$1,388
2018
$2,862
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$195
Incyte Corporation
$152
Janssen Biotech, Inc.
$143
GENZYME CORPORATION
$131
Eisai Inc.
$102
PharmaEssentia USA Corporation
$71
E.R. Squibb & Sons, L.L.C.
$69
Daiichi Sankyo Inc.
$66
Bayer Healthcare Pharmaceuticals Inc.
$61
Mirati Therapeutics, Inc.
$60
PUMA BIOTECHNOLOGY, INC.
$58
Rigel Pharmaceuticals, Inc.
$54
Azurity Pharmaceuticals, Inc.
$43
ARRAY BIOPHARMA INC
$41
Merck Sharp & Dohme LLC
$26
Acrotech Biopharma Inc.
$25
SOBI, INC
$24
AstraZeneca Pharmaceuticals LP
$22
Exelixis Inc.
$22
Novartis Pharmaceuticals Corporation
$19
Karyopharm Therapeutics Inc.
$16
Lilly USA, LLC
$13
Top 3 companies account for 34.6% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$3,571
Takeda Pharmaceuticals U.S.A., Inc.
$1,643
Janssen Biotech, Inc.
$820
GENZYME CORPORATION
$626
Incyte Corporation
$617
PFIZER INC.
$547
Astellas Pharma US Inc
$413
E.R. Squibb & Sons, L.L.C.
$388
Amgen Inc.
$376
Eisai Inc.
$333
Lilly USA, LLC
$299
SANOFI-AVENTIS U.S. LLC
$199
NOVARTIS PHARMACEUTICALS CORPORATION
$167
AstraZeneca Pharmaceuticals LP
$163
Puma Biotechnology, Inc.
$109
Celgene Corporation
$109
EISAI INC.
$102
Merck Sharp & Dohme LLC
$94
Rigel Pharmaceuticals, Inc.
$91
ARRAY BIOPHARMA INC
$85
SOBI, INC
$84
Dova Pharmaceuticals
$83
Bayer HealthCare Pharmaceuticals Inc.
$83
Mirati Therapeutics, Inc.
$83
Karyopharm Therapeutics Inc.
$81
Sobi, Inc
$80
Pharmacyclics LLC, An AbbVie Company
$80
Bayer Healthcare Pharmaceuticals Inc.
$78
Abbott Laboratories
$75
PharmaEssentia USA Corporation
$71
Daiichi Sankyo Inc.
$66
Exelixis Inc.
$64
PUMA BIOTECHNOLOGY, INC.
$58
Kite Pharma, Inc.
$44
Azurity Pharmaceuticals, Inc.
$43
Shield Therapeutics Inc
$42
Merck Sharp & Dohme Corporation
$40
Alexion Pharmaceuticals, Inc.
$39
Global Blood Therapeutics, Inc.
$37
Taiho Oncology, Inc.
$37
Seagen Inc.
$27
Acrotech Biopharma Inc.
$25
GlaxoSmithKline, LLC.
$22
Clovis Oncology, Inc.
$21
Verity Pharmaceuticals Inc.
$17
Gilead Sciences, Inc.
$16
Top 3 companies account for 49.7% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · CABOMETYX · CALQUENCE · CERDELGA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELITEK · ELREXFIO · ERLEADA · Enhertu · Erleada · IBRANCE · IMBRUVICA · INLYTA · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · LONSURF · LUMAKRAS · Lenvima · NERLYNX · NETSPOT · NINLARO · Neulasta · Nexavar · Nplate · Nubeqa · OPDIVO · OPDUALAG · OXBRYTA · PIQRAY · PROMACTA · Pacemakers · Pomalyst · REBLOZYL · RETEVMO · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SUTENT · Stivarga · TAGRISSO · TECVAYLI · TUKYSA · Tavalisse · Trelstar · Trodelvy · ULTOMIRIS · VELCADE · VERZENIO · VIVIMUSTA · XALKORI · XGEVA · XPOVIO · XTANDI · Xtandi · Yescarta · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (60%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
717
Per 100K population
27.1
County median income
$78,548
Nearest hospital
NEW YORK COMMUNITY HOSPITAL OF BROOKLYN, INC.
1.8 mi
1.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rambhia is a clinical cardiology specialist, with above-average Medicare volume (top 25% in NY), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rambhia experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Rambhia performed 761 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rambhia receive payments from pharmaceutical companies?
Yes. Dr. Rambhia received a total of $12,148 from 46 companies across 319 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rambhia's costs compare to other hematology & oncology specialists in Brooklyn?
Dr. Rambhia's average Medicare payment per service is $63. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rambhia) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Brooklyn
Browse hematology & oncology specialists in Brooklyn ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology